MedPage Today

New Pill Approved for Schizophrenia, Bipolar Disorder

Vanda submitted data from iloperidone's schizophrenia and bipolar I disorder trials to the FDA to support the efficacy and ...
PharmiWeb

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpointsPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today ...
Le Lézard

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (?)-Thalassemia

Bristol Myers Squibb today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in ...